×

RNS Number : 9943Z

Veltyco Group PLC

21 December 2017

 

 

21 December 2017

 

Veltyco Group plc

("Veltyco", the "Company" or the "Group")

 

Blockchain and Cryptocurrency

 

 

The Board of Veltyco Group plc (AIM:VLTY), the online marketing company for the gaming industry, is pleased to announce that is has commenced discussions with blockchain and cryptocurrency providers to enter into partnerships to enable Veltyco's customers to use cryptocurrencies to create one wallet for the Group's various operating partners in the gaming industry.

A cryptocurrency is a digital currency in which certain principles of cryptography are used to regulate the generation of units of currency and verify the transfer of funds, operating independently of any central bank.  Cryptography is used to secure the transactions and to control the creation of new coins. 

Veltyco is planning to offer its customers the use of a crypto wallet that can be used across the platforms of all of Veltyco's partners, allowing customers access to each platform without having to make separate deposits on the individuals platforms as well as enabling Veltyco to cross-sell the different platforms to its customer base.

Veltyco will provide further updates in this regard as appropriate.

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

 

For further information, please contact:

 

Veltyco                                                                                                      +44 (0)16 2460 5764

David Mathewson, Chairman                                    

Marcel Noordeloos, CFO

 

Strand Hanson Limited (Nominated Adviser)                            +44 (0)20 7409 3494

James Harris

Richard Tulloch

James Dance

 

Northland Capital Partners Ltd (Broker)                                      +44 (0)20 3861 6625

Tom Price

 IFC Advisory (Financial PR)                                                              +44 (0)203 053 8671

Graham Herring

Tim Metcalfe

Miles Nolan

 

About Veltyco

Veltyco is a group of companies primarily focused on generating marketing leads and entering into marketing contracts for the activities of various partners in the gaming industry.  Veltyco focuses on complementary activities under one umbrella, leveraging its historical cash generative activities of marketing online casinos and sports betting. 

Website: http://www.veltyco.com

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCBRBDDIBDBGRG

Close

×

RNS Number : 8603Z

Midatech Pharma PLC

20 December 2017

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients

 

Trial to be conducted at the Dana-Farber / Brigham and Women's Cancer Center to determine ability to improve OM outcomes and reduce overall hospitalisation costs

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announced its US subsidiary has initiated a Phase IV clinical trial at Dana-Farber/Brigham and Women's Cancer Center to study the effects of Gelclair® (bioadherent oral gel) on various aspects of oral mucositis (OM), a common side effect experienced by patients undergoing stem cell transplant.

 

Approximately 200 centers across the United States treat 20,000 patients with stem cell transplant therapy (SCT) on an annual basis. One of the most frequently observed side effects of SCT is severe OM, an intensely painful inflammation of the surface of the mouth, which may lead to the need for supplemental prescription pain products (such as opioids), parenteral nutritional therapy and which may result in extended time to patient discharge from highly specialised SCT units, resulting in increased healthcare costs.

 

This trial is a blinded, randomised, controlled study designed to investigate the efficacy and tolerability of Gelclair and the ideal timing of initiation of therapy for the management of OM in allogeneic stem cell transplant recipients conditioned with high-dose chemotherapy.  Understanding how best to use Gelclair to address OM pain, incidence, and severity, as compared to the use of standard of care practices, will help to optimise how health care providers support their patients as they manage this common side effect of stem cell transplantation.

 

Based on Symphony Health Solutions data, Gelclair is the leading gel barrier prescription product prescribed for OM in the retail sector. Gelclair has been used effectively on thousands of ambulatory patients who suffer from OM due to various cancer therapies such as radiation and chemotherapy.  The newly initiated trial in SCT will provide data on the applicability of Gelclair therapy for OM caused by SCT; which, if positive, would support the use of Gelclair in the in-hospital setting.

 

"Oral mucositis causes significant discomfort and pain in SCT patients, and may delay hospital discharge or result in the use of additional and costly therapies," said David R. Benharris, Midatech Pharma U.S. President. "We have worked collaboratively with the experts at Dana Farber to design a trial that will provide health care professionals the necessary information to determine if Gelclair can help SCT units better manage or prevent the symptoms and additional issues related to oral mucositis which are commonly seen in this patient population."

 

The company anticipates that the trial will complete enrollment in the second half of 2018.

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Nick Brown

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and other therapeutic areas, and marketing these through its established US commercial operation which includes four cancer care supportive products and two further co-promoted products.  Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions.  The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

About Gelclair® (Bioadherent oral gel)

Gelclair® is an easy-to-use bioadherent oral gel indicated for the management and relief of pain of various etiologies, including oral mucositis/stomatitis, irritation due to oral surgery, ulcers caused by braces or ill-fitting dentures, disease, and for diffuse aphthous ulcers. Gelclair® has a unique formulation and does not contain alcohol, thereby reducing the risk of painful burning and drying. Gelclair® has been broadly studied, demonstrating rapid and effective relief of pain, improvement in patients' ability to eat and drink and reducing the need for rescue analgesics. Midatech has exclusive U.S. commercial rights to Gelclair® through a license agreement with Helsinn Healthcare SA in Switzerland.

 

Gelclair® Important Safety Information

Do not use Gelclair® if there is a known or suspected hypersensitivity to any of its ingredients. No adverse effects have been reported in clinical trials, although post marketing reports have included infrequent complaints of burning sensation in the mouth. Do not eat or drink for at least 30-60 minutes following treatment. If Gelclair® is swallowed accidently, no adverse effects are anticipated.

 

For additional information, including a copy of the Full Prescribing Information, please visit our web site at www.gelclair.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

UPDUKAORBUAUAUA

Close

×

RNS Number : 7233Z

Prospex Oil and Gas PLC

19 December 2017

 

Prospex Oil and Gas Plc / Index: AIM / Epic: PXOG / Sector: Oil and Gas

19 December 2017

Prospex Oil and Gas Plc ('Prospex' or the 'Company')
Acquiring up to 49.9% of proven gas project in southern Spain

 

Prospex Oil and Gas Plc, the AIM quoted investment company, is pleased to announce it has agreed to acquire up to a 49.9% interest in the Tesorillo Project ('Tesorillo' or 'the Project') in southern Spain ('the Acquisition').  Tesorillo contains a known gas discovery, which a Competent Person's Report undertaken by Netherland Sewell and Associates ("NSAI") in 2015 estimated could hold gross unrisked Prospective Resources of 830 billion cubic feet of gas (Best Estimate), with upside in excess of 2 Tcf.  The Acquisition is in line with the Company's strategy to build a portfolio of high impact onshore and shallow offshore European opportunities with short timelines to production.  This year the Company has acquired interests in three onshore European projects and participated in the drilling of two new wells, both of which have resulted in gas discoveries. 

 

Tesorillo: multiple development/appraisal gas plays with company-making potential

·    Comprised of two petroleum exploration licences, the Tesorillo and Ruedalabola Permits, covering 38,000ha in a proven hydrocarbon region in the Cadiz Province of southern Spain

·    Tesorillo contains the Almarchal-1 discovery well ('Almarchal' or 'the Well'), which was drilled in 1956 by Spanish operator Valdebro

o The Well intersected a thick section of possible gas pay including some zones which flowed gas to surface on testing

o Located on a gravity and seismically delineated thrust ramp anticline, with closure area exceeding 70 km2 and multi-Tcf potential

o Drillstem tests and log analysis confirm 48m of gas pay from two Miocene Aljibe Formation sandstone intervals, with a further 492m of potential gas pay interpreted from logs but unconfirmed by testing

·    Ruedalabola contains 1957 Puerto de Ojen-1 well, 15km to the east of Almarchal which displayed similar gas shows to Almarchal but could not be tested for mechanical reasons

·    Large Resource: unrisked prospective resource of 830 Bcf (Best Estimate), with upside in excess of 2 Tcf independently certified by NSAI in May 2015 (see table below for further details)

·    Excellent access to infrastructure: Project located 3.9 km from the North African Maghreb gas pipe line European landing point providing access to high priced European gas markets  

 

Three stage acquisition process

·    Acquiring up to 49.9% of Schuepbach Energy Espania S.R.L. ("SEE"), which has a 100% interest in Tesorillo, from Schuepbach Energy International LLC ("SEI") in three tranches:

o Stage 1: buy 2.50% for €48,750, effective immediately

o Stage 2: option to buy another 12.50% for €280,000 (increasing stake to 15%)

o Stage 3: option to buy a further 34.9% for €1,725,000 when drilling of a well is due to commence (increasing stake to 49.9%)      

·    Prospex's take up of the Stage 2 and 3 options will be based on the results of an upcoming work programme planned by SEE to further delineate and de-risk the Project's prospectivity.  It is envisaged that on acquisition of the third tranche a drill programme would have been agreed

 

Similar geology to existing portfolio of investments in European onshore projects

·    Tesorillo is a much larger variant of the fore-deep play which Prospex successfully tested with two recent discoveries in Romania and in Italy

o Bainet gas discovery on Suceava in Romania due to commence production in Q2 2018

o Podere Maiar-1d well in the Po Valley of Italy where flow testing is due to commence shortly

 

Prospex Exploration Manager, Carlos Venturini, said, "The external sector of the Western Baetic Cordillera of Spain is possibly the final under explored basin with conventional hydrocarbons potential in the country.  Exploring this area will allow us to test gas bearing sandstone sequences which are already known, within a variant of the fore-deep play which we have successfully tested with two recent discoveries in Romania and in Italy."

 

Prospex non-executive Chairman, Bill Smith, said, "Tesorillo offers the potential for very significant growth during 2018 and 2019 and caps a highly active and successful year for Prospex.  In line with our strategy we have acquired interests in three onshore European projects and participated in the drilling of two new wells, both of which have resulted in gas discoveries.  As with our Suceava Concession in Romania and the Podere Gallina Exploration Permit in Italy, Tesorillo offers multiple development and appraisal gas opportunities.  With independently certified unrisked prospective resource of 830 Bcf (Best Estimate), with upside in excess of 2 Tcf, the company-making potential of our latest investment is clear.  We are confident our in-house experience and wide European industry network will provide invaluable knowledge in assisting SEE to take this very exciting project to the next stage and beyond. 

 

"We expect to build on the momentum behind the Company in the year ahead.  This will see the Bainet gas discovery brought on line in Romania; flow testing at the Podere Maiar-1d well in Italy and the commencement of a work programme at Tesorillo to de-risk further the prospectivity that has already been mapped.  In parallel with this, we continue to evaluate additional projects that match our criteria, as we look to build a pipeline of value trigger events each of which have the potential to generate significant value for our shareholders and a re-rating of the Company.  We look forward to keeping our shareholders updated on progress in the New Year."

 

Acquisition Details:

 

PXOG Muirhill Ltd ("Muirhill"), a wholly owned subsidiary of Prospex, has entered into a Share Purchase Agreement ("SPA") with SEI to acquire up to 44,910 ordinary shares of SEE ("SEE Ordinary Shares"). The shares not acquired are owned by SEI.  The initial purchase of 2,250 SEE Ordinary Shares is for a consideration €48,250.  The SPA provides for Muirhill, at its sole discretion to acquire a further and second tranche of 11,250 SEE Ordinary Shares for a consideration of €280,000 by 31 December 2018.   Purchase of the second tranche of SEE Ordinary Shares would take Muirhill's total holding to 15% of the entire issued share capital of SEE.  The SPA provides for Muirhill at its sole discretion to acquire a further tranche of 31,410 SEE Ordinary Shares for a consideration of €1,725,000 before the mid-way point of the sixth year of the licence.  Purchase of the third tranche of SEE Ordinary Shares would take Muirhill's total holding to 49% of the entire issued share capital of SEE.  The SPA restricts the issuance of new SEE Ordinary Shares or options over such shares in the period to acquisition of the third tranche and contains the usual provisions and warranties for an agreement of this nature.

 

As part of the arrangements Muirhill will enter into a secured loan facility with SEI to provide SEI with initial funds for its share of SEE's working capital of up to €126,750.  The security to be provided is 5,100 SEE Ordinary Shares held by SEI.  The loan facility will incur interest at 3 per cent per annum, to accrue until repayment of the principal.  The loan amount is repayable at the Second Closing (as defined in the SPA), when the acquisition of the second tranche of shares completes.  Muirhill, SEI and SEE have entered into a detailed Shareholders' Agreement ("SHA") to regulate the future relationship between SEE and its shareholders.

 

Under the terms of the SHA the parties have agreed to fund their share of the costs going forward in line with their respective proportional ownership. The SHA is consistent with others recently entered into by Prospex and its subsidiaries.  It contains usual industry standard provisions for sole risk, default and for the operations and directional control of SEE.

 

ASX quoted Petrel Energy Limited (ASX Code: PRL), an Australian based petroleum exploration, development and production company, owns 63% of SEI, with Schuepbach International Holdings LLC holding the remaining 37%. Schuepbach International Holdings LLC is a Delaware corporation and is part of the Schuepbach Energy Group, a private equity back group with activities in United States, Spain, Switzerland and Uruguay.

 

Further details on the Permits:

The permits received Royal Decree on December 2010 and following partial relinquishment in 2014 cover a combined area of 382 square km.  The permits were awarded for an initial six-year term, 4 + 2, but in July 2016 the Ministry of Energy ordered that the clock stopped in October 2013, toward the end of the third year.  The annual work commitment for the first term has been met.  The remaining work commitment is one well.

 

In May 2015 Netherland Sewell and Associates ("NSAI") independently certified an unrisked Prospective Resource of 830 billion cubic feet of gas (best estimate) with upside in excess of 2 TCF for the Tesorillo Project as outlined below:

 

Tesorillo	Prospective Resource BCF(Gross)	Original Gas In Place BCF (Gross)
Low Estimate (P90)	220	734
Best  (Median) Estimate (P50)	830	1,661
High Estimate (P10)	2,289	3,270

 

 

The estimates of gross volumes for each prospect were determined by Mr Dan Walker, of Netherland, Sewell and Associates Inc., Dallas, Texas, USA, on 5 May 2015, in accordance with Petroleum Resources Management System guidelines.

 

 

SEE expects to restart activities on the permits shortly with the passive MT survey, the work for which already has government approval.

 

 

Carlos Venturini, Fellow of the Geological Society of London, Exploration Manager has reviewed and approved the technical information contained within this press release in his capacity as a qualified person, as required under the AIM Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

* * ENDS * *

 

For further information visit www.prospexoilandgas.com or contact the following:

 

Edward Dawson	Prospex Oil and Gas Plc	Tel: +44 (0) 20 3766 0325
Rory Murphy Ritchie Balmer Jack Botros	Strand Hanson Limited	Tel: +44 (0) 20 7409 3494
Jon Belliss	Beaufort Securities Limited	Tel: +44 (0) 20 7382 8300
Duncan Vasey	Peterhouse Corporate Finance	Tel: +44 (0) 20 7469 0932
Frank Buhagiar Charlotte Page	St Brides Partners Ltd	Tel: +44 (0) 20 7236 1177

Notes

Prospex Oil and Gas Plc is an AIM quoted investment company focused on high impact onshore and shallow offshore European opportunities with short timelines to production. The Company's strategy is to acquire undervalued projects with multiple, tangible value trigger points that can be realised within 12 months of acquisition and then applying low cost re-evaluation techniques to identify and de-risk prospects. 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

ACQFFISSUFWSEFE

Close

×

RNS Number : 7234Z

Redhall Group PLC

19 December 2017

 

For immediate release	19 December 2017

 

 

 

Redhall Group plc

("Redhall" or the "Company")

 

Jordan Manufacturing Wins Nuclear Contract

 

Redhall (AIM: RHL), the high integrity manufacturing and services group, announces that its Jordan Manufacturing business has secured a key role in support of Cavendish Nuclear, a subsidiary of Babcock International Group PLC ("Babcock"), for the delivery of specialist handling and containment systems to process nuclear material for Sellafield Ltd ("Sellafield").

 

Babcock announced on 18 December 2017 that Cavendish Nuclear has been awarded a 10-year contract with Sellafield. Worth up to £95 million over the first three years, Cavendish Nuclear will provide Sellafield with design, manufacture and supply of complex bespoke equipment for the treatment and management of nuclear materials.

 

Jordan Manufacturing has secured, through a Teaming Agreement with Cavendish Nuclear, a key role in the delivery of this contract and will manufacture containment systems and associated process equipment.  It is anticipated that this will be worth up to £18 million over the first three years.

 

Phil Brierley, CEO of Redhall, said: "We are delighted to have secured a key role supporting Cavendish Nuclear in the delivery of this strategically important programme. This opportunity clearly reflects the capabilities Jordan Manufacturing has developed over many years in the supply of highly complex containment systems and gives the business good visibility over its order book for a number of years to come."

 

Contact details:

 

Redhall Group plc	Tel: +44 (0) 1924 385 386
Phil Brierley, Chief Executive Chris Kelly, Group Finance Director Wayne Pearson, Chief Operating Officer
Buchanan, PR Adviser	Tel: +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Gemma Mostyn-Owen
GCA Altium, Financial and Nominated Adviser
Tim Richardson, Simon Lord	Tel: +44 (0) 20 7484 4040
WH Ireland, Broker
Adrian Hadden, Ed Allsopp	Tel: +44 (0) 20 7220 1666

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTEAEANFAEXFEF

Close

×

RNS Number : 5736Z

Croma Security Solutions Group PLC

18 December 2017

 

CROMA SECURITY SOLUTIONS GROUP PLC

("CSSG" or the "Group")

 

New Contract Win

 

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulations No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

 

Croma Security Solutions Group Plc is delighted to announce a very significant contract win. The contract with a major UK local authority is the largest the group has ever won. The 6 year contract for the provision of a range of security services is worth £27m in total.

Sebastian Morley Chairman of CSSG comments:

"This contract award is extremely significant and is the largest that the Group has won to date. It is a testament to the unique offering that Croma Vigilant brings to the market. The ex-military ethos of the business is resonating strongly with both our clients and our staff; majoring on discipline, operational excellence and continuity. We are delighted with this award and its effect upon the Group's development. We look forward to updating the market further in the new calendar year."

 

For further information contact:

 

Croma Security Solutions Group plc Sebastian Morley, Chairman	Tel: +44 (0)7768 006 909
WH Ireland Limited (NOMAD and Broker) Mike Coe / Jessica Cave	Tel: +44 (0)207 220 1666

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTBQLLFDLFXFBL

Close

×

RNS Number : 6148Z

Gunsynd PLC

18 December 2017

 

Gunsynd plc

 

("Gunsynd" or the "Company")

 

Investment in Human Brands

 

Gunsynd Plc (AIM: GUN, NEX: GUN) is pleased to announce that it has invested £130,000 in Human Brands plc ("Human Brands"), a US based premium spirits company, on the following terms:

 

·     £130,000 invested by way of convertible loan note ("Loan Note");

 

·     The Loan Note will accrue interest at 9% per annum;

 

·     The repayment of the Loan Note is due on the 30th day of the 24th month after the date of issue of this note ("Repayment Date").  The payment at maturity will include the principal amount of the Loan Note plus all accrued interest;

 

·     While currently not quoted on any exchange, Human Brands intends to seek admission to trading on an exchange during 2018. The Company shall be entitled at any stage after the date falling thirty (30) days after Human Brands has achieved trading status on a recognised securities exchange and prior to the Repayment Date to convert all or any part of the Loan Note (and any outstanding interest thereon) into ordinary shares in the capital of Human Brands; and

 

·     The Loan Note shall be converted into ordinary shares of Human Brands at a price equal to a 55% discount to the three day average volume weighted average price of the shares as recorded immediately prior to the conversion date.

 

 

About Human Brands

Human Brands is a private US company that produces, distributes and markets premium spirits, wine and beer in the USA and Asia. Their two key products, which they both own the brand of and distribute, are an aged tequila (Copa Imperial Tequila) and a Japanese Whiskey (Shinju Whiskey) which are in two of what the Directors believe to be the fastest growing areas of the US spirits industry.  In the year ended 31 December 2016, Human Brands had turnover of $1.04m and profit after tax of $90k.

 

 Hamish Harris, the Company's Executive Chairman, commented:

"We are very pleased to have been able to subscribe on very attractive price in to a company well positioned in the growth areas of the premium spirits industry.  We expect to have newsflow in Q1 next year  on many fronts not least on Oyster Oil and Gas and Sunshine Mineral but also on Horse Hill Developments and Brazil Tungsten holdings, all of which we are very much looking forward to."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The directors of Gunsynd accept responsibility for this announcement.

 

For further information please contact:

 

Gunsynd plc Hamish Harris	+44 20 7440 0640
Cairn Financial Advisers LLP James Caithie / Sandy Jamieson	+44 20 7213 0880
Peterhouse Corporate Finance Lucy Williams	+44 20 7469 0930

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCFMMMZRRNGNZG

Close

×

Neville Registrars is delighted to welcome Genagro Ltd as the newest addition to its list of client companies.

Genagro Ltd is an investor in Brazilian farmland. Further information can be found on the Company's website: http://www.genagro.net/

Close

×

RNS Number : 0232Z

Plant Health Care PLC

12 December 2017

 

12 December 2017

Plant Health Care plc
(the "Company" or "Plant Health Care")
New Technology Update

Plant Health Care® (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

–  A fifth major agricultural/seed company has now signed an agreement to evaluate Innatus™ 3G; all five of the top agricultural/seed corporations are now testing Innatus 3G in the field. 

–  Four of these companies have now started field trials of Innatus 3G in Brazil for the control of Asian Soybean Rust ("ASR"), a devastating disease of soybeans. Plant Health Care's lead peptide for control of ASR is PHC279; this is now being produced by high yield fermentation at pilot scale.

–  Exclusive rights to Innatus 3G for use in South American soybeans are expected to be auctioned in mid 2018, before the start of the 2018/19 growing season.

–  The Company has decided to focus its New Technology resources on delivering successful auctions in 2018.  Closing a licensing event in 2017 has been de-prioritised to focus on the larger 2018 goals.

Innatus 3G

A fifth major agricultural/seed company has signed an agreement to evaluate Innatus 3G. That means all five of the top agricultural/seed corporations are now investing significant resources on field testing our PREtec platforms.

Recent field trials commissioned by Plant Health Care provide further support for the benefits of Innatus 3G peptides in the control of ASR, a devastating fungal disease of soybeans in Brazil.  Farmers spent US$1.7 billion on soybean fungicides in 2016 in Brazil*; in spite of this investment, ASR resistance to fungicides is a major problem.  Four partners, which between them represent more than 80% of this fungicide market, are now testing Innatus 3G, with results due in 2Q 2018.

In addition to the partners' trials, the Company is collaborating with EMBRAPA, the highly regarded Brazilian Government agriculture research organisation, to evaluate Innatus 3G.   There are good prospects of fast track registration for Innatus 3G, due to its benign biological profile.

To support all of this work in Brazil, the company has established Plant Health Care Insumos Agricolas Ltda, a wholly owned subsidiary.

In parallel, the Company is developing peptide production processes at our laboratories in Seattle.  The lead candidate peptide (PHC279) has achieved yield targets at laboratory scale and has moved to pilot-scale fermentation.

Exclusive rights to Innatus 3G for use in South American soybeans are expected to be auctioned in mid 2018, well ahead of the start of the 2018/19 growing season.  We are engaging actively with all our major partners to prepare for that auction.

Partners are starting to indicate promising results in 2017 trials with T-Rex 3G and Y-Max 3G.  Supporting the large Innatus 3G field programme in Brazil and accelerating the development of a commercial formulation of PHC279 are now the company's top development priorities.  Since these priorities require substantial resource, the Company has decided to de-prioritise closing a licensing event in 2017, in order to underpin success with the larger 2018 goals.

Chris Richards, Executive Chairman & Interim CEO, said "It is a great landmark to have all the industry majors signed up to work with Innatus 3G.  With the very large resources they can bring to bear, backed up by our own field trials work with EMBRAPA and others, we are confident that the field trials now started will generate the data our partners need to evaluate the platform.  If Innatus 3G lives up to its promise of fighting disease resistance, we can be confident of a successful auction of rights to South American soybeans in 2018."

 

Enquiries:
Plant Health Care plc
Dr Chris Richards, Executive Chairman and Interim CEO	Tel: +44 (0) 18 3788 0083
Liberum Capital – Nomad and Broker
Chris Clarke / Clayton Bush / Jonathan Wilkes-Green	Tel: +44 (0) 20 3100 2000
Company website: www.planthealthcare.com

 

*Source: Phillips McDougall

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RESGGGMUPUPMPGG

Close

×

RNS Number : 8919Y

Yu Group PLC

11 December 2017

 

11 December 2017

RNS Reach

Yü Group PLC
("Yü Group" or the "Group")

 

Licence granted to supply water market

 

Yü Group PLC (AIM: YU.), the independent supplier of gas and electricity to the UK corporate sector, announces that it has been granted a licence by regulator Ofwat to enter the retail and commercial water market. The Company intends to supply water services for the business sector only and will trade under the Company's newly formed subsidiary, Yü Water Limited ("Yü Water").

 

Yü Group decided to launch Yü Water following the de-regulation of the water retail market in April this year, the largest market of its kind in the world. The licence will allow Yü Water to buy wholesale water services and offer these services together with its energy services to develop bespoke packages to suit the individual business needs of its customers.

 

Commenting on the news, Ofwat senior director Emma Kelso said: "It's good news to see suppliers bring different areas of expertise to the water market – with Yü Water bringing theirs from a background in energy."

 

Bobby Kalar, Chief Executive of Yü Group, said: "The addition of the water utility services to our product portfolio builds on our experience in the energy market for corporate customers and our ability to deliver these utilities with best-in-class customer service. Our focus remains on our core offering in the provision of energy, however this enables us to offer a bespoke, value-added service to our customers who seek the flexibility of a one-stop-shop for their utility needs. We see long term opportunities for the Company in the water industry."

 

For further information, please contact:

Yü Group PLC Bobby Kalar Nick Parker	+44 (0) 115 975 8258
Alma PR John Coles Hilary Buchanan Robyn Fisher	+44 (0) 20 8004 4217

 

Notes to Editors

Information on the Group

Yü Group PLC, trading as Yü Energy, is an independent supplier of gas and electricity focused on servicing larger corporate and SME businesses throughout the UK. It has no involvement in the domestic retail market. The Group was listed on the AIM market of the London Stock Exchange following a successful IPO in March 2016.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRATMBFTMBBBBJR

Close

×

RNS Number : 6260Y

Verditek PLC

07 December 2017

 

7 December 2017

 

Verditek PLC

("Verditek" or the "Company")

 

Westec Environmental Solutions signs Letter of Intent with Industrial Climate Solutions Inc. for the commercialisation of its CO2 absorber technology

 

Verditek plc, (AIM: VDTK), the clean technology company, is pleased to announce that, further to the announcement made on 29 November 2017, its group company Westec Environmental Solutions ("WES") has signed a Letter of Intent ("LOI") with Industrial Climate Solutions Inc. ("ICSI") to develop and enter into a licence agreement for the commercialisation of WES' CO2 absorber technology.

 

ICSI is a Canadian company focused on the development and commercialisation of industrial process equipment and technologies to address greenhouse gas emissions at an industrial scale. WES will work with ICSI for the commercialisation of its CO2 absorber technology, as well as providing technical support. Initial products will focus on gas/liquid contactors for flue gas scrubbing, CO2 capture, industrial gas processing and air quality applications.

 

WES' patented absorption technology, which comprises a uniquely developed contactor, offers new solutions that optimise the mass transfer of gas/liquid for industrial emissions/control and for CO2 capture. Currently WES' technology is in the penultimate phase of its optimisation pilot project, carried out in collaboration with SINTEF (Norway's largest research institute for energy and climate technology) and one of Canada's CMC Research Institutes, the Carbon Capture & Conversion Institute (CMCRI CCCI), prior to scale-up to full industrial volumes.

 

Theo Chapman, CEO of Verditek plc said: "We are delighted to be working with ICSI who bring a wealth of knowledge and experience in helping us bring our technology to market. This commitment reflects the strong progress the team at WES continues to make and validates the significant performance improvements our technology offers compared to conventional technologies. We look forward to finalising the binding agreement with ICSI and updating shareholders in due course."

 

 

Enquiries:

 

Verditek plc    Geoffrey Nesbitt (Non-Executive Chairman) Theodore Chapman (Chief Executive Officer)	+44 (0) 20 7129 1110 [email protected]
Stockdale Securities Limited (NOMAD and Broker)
Antonio Bossi Hanan Lee	+44 (0) 20 7601 6100
Yellow Jersey PR (PR & IR) Georgia Colkin Harriet Jackson Henry Wilkinson	+44 (0) 7825 916 715 +44 (0) 7544 275 882 +44 (0) 7951 402 336

Notes to Editors

 

Verditek plc

 

AIM listed Verditek plc is a holding company with three businesses operating within the clean technology sector. The Company has a unique liquid gas absorption technology expected to revolutionise the global CO2 capture industry; two solar manufacturing production lines in San Marino each of 25MWp (total 50MWp) producing what is believed to be an innovative and un-paralleled solar PV building material; and a pioneering filtration deodorisation technology, which is commercially proven and tackles a wide range of odours within air and water at a high efficiency.

 

For more information please visit or contact the following: https://www.verditek.plc.uk/

 

Westec Environmental Solutions (WES)

 

Verditek plc holds a 23.64% stake in WES, with an option to increase it to 51%. The WES Absorber provides powerful new solutions for all applications where gas/liquid absorption or scrubbing occurs.

 

The WES Absorber froth column is unlike any currently available gas/liquid absorber.

The WES Absorber creates a micro-froth matrix that dramatically intensifies mass transfer. This micro-froth matrix mass transfer provides a remarkable increase in absorption surface area compared to conventional gas/liquid absorbers.

 

The WES Absorber differs from conventional absorption technology by utilizing co-current absorption, rather than counter current. With this, WES is able to operate at gas velocities far in excess of those tolerated in conventional gas/liquid absorbers, without significant solvent losses through entrainment and flooding. The efficiency of the WES process increases with increasing gas velocity- a characteristic truly unique to WES.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRUNSKRBAAURAA

Close